Our key Figures
|
21,700 employeesin 149 countries, including 4,500 in France.
|
|
|
5 major R&D areascardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.
|
|
94 Million patientstreated daily with Servier medicinal products and generics.
|
|
49 servier drugson the global market
|
|
36 drug candidatesin research and development, including 26 new molecular entities.
|
|
16 international centers of clinical developmentand 3 research centers.
|
|
16 chemical and pharmaceutical production sitesproducing chemicals and pharmaceuticals worldwide.
|
|
4,152 billion euros turnovercomprising 2.94 billion euros for Servier and 1.21 billion euros for generics.
|
|
25 % of turnover from Servier drugs is invested in R&Dexcluding generics.
|
|
No. 2 pharmaceutical company in franceno. 30 in the world; 3 research centres including 2 in France.
|
|
No.1 in cardiology in Franceno. 2 in Europe, No. 8 in the world.
|
|
2nd leading preferred partner for research centers conducting clinical trialsAccording to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies
|
|
Servier earned the highest score of A3++As in previous years, this high score represents excellence in honoring financial commitments.
|
|
Participation reached 47.3% of the trade balance surplus in franceIn pharmaceuticals and fine chemicals, amouting to 1.51 billion euros.
|